Thursday, October 3, 2013
When the Broad Institute of MIT and Harvard launched
its Center for the Science of Therapeutics to develop new therapies for
hard-to-hit targets and test them in the clinic, it lacked funds to take
discoveries all the way to approval. The center's new collaboration with Bayer AG fills
that gap for cancer assets and comes on the heels of its infectious disease
arrangement with AstraZeneca plc.
Haas, M.J. SciBX
Published online Oct. 3, 2013
1. Basu, A. et al. Cell;
published online Aug. 29, 2013;
Contact: Stuart L. Schreiber, Broad Institute of MIT and Harvard,
Contact: Alykhan F. Shamji, same affiliation as above
Contact: Paul A. Clemons, same affiliation as above
2. Zack, T.I. et al.
Nat. Genet. 45, 1134-1140 (2013)
AND INSTITUTIONS MENTIONED
AbbVie Inc. (NYSE:ABBV), Chicago, Ill.
AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.
Bayer AG (Xetra:BAYN),
Broad Institute of MIT and Harvard, Cambridge, Mass.
Columbia University, New York, N.Y.
Dana-Farber Cancer Institute, Boston, Mass.
Genentech Inc., South San Francisco, Calif.
Harvard Medical School, Boston, Mass.
Harvard University, Cambridge, Mass.
Howard Hughes Medical Institute, Chevy Chase, Md.
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
Vanderbilt University School of Medicine, Nashville, Tenn.